3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
(PLUS ticker 3DDP)

Appointment of Non-Executive Director

3D is pleased to announce the appointment of Christina Rawlinson as a non-Executive director with immediate effect.

Christina is a Fellow of the Association of Chartered Certified Accountants and a member of the Compliance Institute. Christina is a senior employee with Cavendish Trust Company Limited which is licensed by the Isle of Man Financial Supervision Commission as a Corporate and Trust Service Provider. Christina was a director of Pactolus Hungarian Property plc pre-IPO and retained her position as a director after the company's successful admission to AIM. She has extensive experience in business strategy, development and marketing.

Graham Lay, Chief Executive Officer of 3D Diagnostic Imaging said, "Chistina's appointment strengthens our board further, broadening our skills set and putting 3D in the best position to grow."

Christina Rawlinson commented, "3D is an exciting business and I am delighted to accept this appointment."

 

For further information please contact:

3D Diagnostic Imaging Plc Graham Lay, CEO Oliver Cooke, FD	+44 (0) 1382 560 910 +44 (0) 207 368 6959
FinnCap Geoff Nash, Henrik Persson,	+44 (0)20 7600 1658
Buchanan Communications Diane Stewart, Carrie Clement	+44 (0) 207 466 5000

Further information required pursuant to Paragraph 18 of Appendix I of the PLUS Rules for Issuers:

 

Names of all companies and partnerships of which such person has been a director or partner during the previous five years	Current directorships: 3D Diagnostic Imaging plc Applaud Investments Limited Bellisima Limited Cargo Inspections International Limited Ceilidh Limited Chatham Limited Cubit Investments Limited Enbrook Limited Hensol Limited Jerusalem GP Limited Mannifest Limited Touchstone Investments Limited   Previous directorships: Anglo Aviation Limited Anglo Irish Tryust (IOM) Limited Archoff Limited Berkeley (Carnwath Road) Limited Berkeley Investments (IOM) Limited Castlebay Limited Compton Limited Dulson Unlimited Equiom Nominees Limited Equiom Trust Company Limited Malokan Limited Red Forest Limited River Court Properties Limited Silver Limited Vadine Limited Academy Limited Acresfield Limited Ailsa Solihull Limited Alderbrook Limited Alderton Partners Limited Alexan Limited Alfano Limited Alina Limited Almark Limited Alsina Limited Alstone Partners Limited Alvaro Limited Amber Park Limited Antigo Limited Apollomia Limited Ariel Enterprises Limited Arner Limited Arta Group Limited Arvan Limited Ashbourne Beech Property Limited Ashbourne Cedar Property Limited Ashbourne No 1 Limited Ashbourne No 2 Limited Ashbourne Property Limited Ashbourne Property No.2 Ltd Aston Partners Limited Atlantic Park Limited Autumn Park Limited Avantier Enterprises Limited Balcombe Limited Bandler Limited Barella Limited Baros Enterprises Limited Baytown Limited Baytown Properties PCC Limited Beckdale Limited Betpoint Limited Bingham Limited Birchleigh Limited Bisley Partners Limited Bjork Overseas Limited Borneal Limited Bradfield Limited Bridgestream Limited Brimpsfield Partners Limited Bruce Betting (Isle of Man) Limited BSP Keyboards Limited Buckland Partners Limited Bugnano Condominium Company Limited Burwell Limited Cambridge Place (Securities) Limited Cambridge Place CDO (Isle of Man) Limited Cansas Investments Limited Carenza Limited Carlito Limited Carloway Limited Castlelyon Limited Charnock Limited Chedworth Partners Limited Cherington Partners Limited Clearmount Investments Limited Cobra Shores Limited Collingwood Limited Commander Shipping Limited Computer Associates Limited Confidence Shipping Limited Copperwood Limited Coralmar Limited Courtway Limited CP Investments (General Partner) Limited Crystal Horizon Limited DB System Trade Limited Damron Limited Danethorpe Limited Dante Limited Dazar Unlimited Denaway Limited Denbigh Developments Limited Diamond Lady Limited Dill Limited Dino Limited Dodman Limited Dorset London West Limited Driscoll Limited Dumford Limited Eagle Welwyn City LLC East London Residential Property Limited Eastfield Park Limited Ebttikar Limited Echo Point Limited Edenderry Limited Electro Technology Systems Limited Elm Park Properties Limited EMC Payor Limited Employee Plan General Partner Limited Endfield Park Limited Energy Holdings Limited Equiom Corporate Services Limited Equiom Nominees (Trusts) Limited Equiom Nominees Limited Ernst & Young Holdings Limited EWM Limited Exeter Shipping Limited Fanorder Limited Fellstar Limited Fenlay Limited Follingworth Limited Force Majeure Consulting Limited Fortino Limited Frampton Limited Freshford Partners Limited Futurian Limited GBM Limited Ganges Investments Limited Gannon Farnham Guildford Limited Gila Limited Gilbertstown Limited GIP Company Limited Glass of Beer Limited Gleniffer Limited Glenthorn Limited Global Consulting Services (IOM) Limited Goldhill Limited Grace Investments Limited Graphex Limited Grayson Limited Greet Partners Limited Gretton Partners Limited Greyfriar Limited Hadleyville Limited Hadrian Limited Hadstock Limited Hanso Limited Hanwell Limited Harston Limited Hashamach Limited Haversham Limited Hawling Partners Limited Hazel View Limited Hazelbury Limited Heywood Park Limited Hickleton Limited Highford Limited Hogarth Limited Incisor Limited Irton Properties Limited Jarvo Limited Jarwood Limited JC Payor Limited Jimzola Limited Jubilee Limited Kailas Communications Limited Karolina Investments Limited Keiko Limited Keith Wood Promotions Limited Kendra Limited Kentwell Limited Kerelem Limited Kernesk Limited Kiel Limited Kildon Limited Kilone Limited Kingsholm Limited Koban Limited Krypton Enterprises Limited Kyvis International Limited Ladyland Limited Laine Limited Lambley Park Limited Lansley Limited Laurel Dawn Limited Leftfield Limited Leixlip Limited Lemarate Properties Limited Leslington Limited Liam Brady Promotions Limited Littleton Limited Longbay Limited Luxton Limited Mariella Limited Marine & Fuel Marketing (IOM) Limited Marisco Limited Martlet Company Limited Maya Hyde Park Limited Maypark Limited Maypark One Limited Mellor Limited Melody Limited Merryvale Limited Mollington Limited Moreton Limited Moyville Enterprises Limited Newbury Trustee No 1 Limited Newbury Trustee No 2 Limited Nocturne Limited Norminster Limited Northrise Limited NYX Interactive Network IOM Limited Oakby Limited Oakford Property Company Limited OTR Global Research Limited P.K. Enterprises Limited Pactolus Hungarian Property PLC Pactolus (IOM) Limited Padlock Limited PDC Agencies Limited Pelman Investments Limited Pentagon Investments Limited Petersen Limited Polar Dawn Limited Portwall One Limited Prada Limited Q Technologies, Ltd Quadrille Investments Limited Quill Hemel Hempstead Limited R.S. & B.S. Limited Rail Road Consultants Limited Rebilac Limited Rebilac Management Limited Red Forest Limited Redbridge Limited Redcastle Capital Limited Redhall Limited Rockware Limited Rodmarton Partners Limited Roseacre Limited Rosina Limited Rotcher Limited Rutilus Investments Limited Sable Limited Salado Enterprises Limited Sandywell Limited Sarando Limited Sartor Limited Seaford Limited Seagrove Limited Shelford Limited Sheps (PHFL) Limited Shiu Kwong Limited Shiu Wing Limited Shoreacres Limited Skyelady Limited Southam Partners Limited Stanford Services Limited Stanton Limited Starcrest Limited Starr Street Limited Starzan Limited Steel Transporter Limited Street 45 Limited Sussex Estates Limited Tailored Solutions Limited Tailwind Parcel Tankers Limited Tajka Limited Talca Enterprises Limited Talent Investment Limited Tango Investments Limited Tarlton Partners Limited Tasman (UK) Limited Tasman Limited Taunton Limited Tenza Guildford Leatherhead Limited TES Company Limited Thoas Ventures Limited Thorstone Limited Thrupp Partners Limited Tiger Bay Limited Timmis Limited Tinas Investments Limited Topwell Limited Troyden Limited Two Plus Three Limited Varadan Limited Villa Park Limited Vollers Payor Limited Volmand Limited Wargrave Partners Limited Wendmore Limited Westmill Limited Westow Limited Whitcombe Limited White Flame Limited Whitehead Limited Wilpot Limited Winsley Limited Winterridge Limited Woodview Limited Yarmouth Limited Yoconaya Limited Zoneff Limited Barsan Limited E H Holdings Limited Lenmore Trading Ltd Tabella Limited Turiminola Limited
Details of any unspent convictions in relation to indictable offences;	None
Details of any administrations, receiverships or insolvent liquidations (including company or partnership voluntary arrangements) of a company or partnership where such person was a director or partner at the relevant time or during the twelve months preceding such events	Pentagon Investments Limited Maypark Limited
Details of any bankruptcy or individual voluntary arrangement; and	None
Details of any official public incrimination or sanction of such person by statutory or regulatory authorities (including designated professional bodies) and whether such person has ever been disqualified by a court from acting in the management or conduct of the affairs of a company.	None

3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
(PLUS ticker 3DDP)

CarieScan signs exclusive Canadian distribution deal with leading distributorPatterson Dental

3D (PLUS : 3DDP) is pleased to announce that, further to the announcement on 2 July 2010, its wholly owned subsidiary CarieScan Limited ("CarieScan"), has entered into a distribution deal with Patterson Dental/ Dentaire Canada ("Patterson").

Under the terms of the agreement, Patterson will have exclusive distribution rights within the Canadian market for the CarieScan PROtm, a highly accurate, easy to use, hand held device for the early detection and monitoring of dental caries (tooth decay). This follows the recent completion of a separate exclusive distribution agreement with Patterson Dental in the USA

Patterson is the largest distributor of dental equipment in Canada covering a dental market of 16,000 dentists.

Commenting on this agreement Graham Lay, Chief Executive Officer of 3D said: "As one of the best represented dental distributors in North America Patterson brings the knowledge and resources to best introduce and achieve sales of our revolutionary early detection and caries monitoring device into the Canadian dental market. Post the US deal we are very excited that the Canadian agreement has followed so quickly and demonstrates the strength of the technology."

 

For further information:

3D Diagnostic Imaging Plc Graham Lay, CEO Oliver Cooke, FD	+44 (0) 1624 679000 +44 (0) 207 368 6959
FinnCap Geoff Nash, Henrik Persson, Stephen Norcross - Broking	+44 (0)20 7600 1658
St Helens Capital Partners LLP Mark Anwyl	+44 (0) 207 368 6959
Buchanan Communications Diane Stewart, Carrie Clement	+44 (0) 207 466 5000

Further information on the CarieScan PRO™

The CarieScan PRO™ measures the presence of tooth decay earlier and more accurately than any other device on the market and is more than 90% accurate in detecting both sound and carious teeth, well ahead of other methods. It detects "hidden" decay, providing dental practitioners with the opportunity to arrest or even reverse decay, driving the trend towards preventative dental care.

The lightweight caries detection monitor not only offers best-in-class performance for decay detection but also allows easy monitoring of the effect of treatment regimes to show decay advancement or regression, thus enabling dentists to tailor treatment to the needs of the patient at a low cost. The CarieScan PRO™ consists of a hand piece and a disposable sensor which is held against the tooth being examined in a process which takes approximately four seconds per tooth with the result displayed on the CarieScan PRO™.

3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
(PLUS ticker 3DDP)

Change of Adviser

The Company is pleased to announce the appointment of FinnCap as PLUS Adviser and Broker with immediate effect.

For further information:

3D Diagnostic Imaging Plc Graham Lay, CEO Oliver Cooke, FD	+44 (0) 1624 679000 +44 (0) 207 368 6959
FinnCap Geoff Nash, Henrik Persson	+44 (0)20 7600 1658
Buchanan Communications Diane Stewart, Carrie Clement	+44 (0) 207 466 5000

 

3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
(PLUS ticker 3DDP)

Additional funding secured to finance growth

Following the recent announcement of the signing of a transformational distribution agreement for the USA with Patterson Dental, the Company is pleased to announce that it has secured £525,000 of additional funding, predominantly from existing shareholders, to enable it to begin the process of implementing the agreement.

The additional funding is to be provided by way of subscription for unsecured convertible loan notes, which will attract interest at the rate of 5% per annum. Subscription for the loan notes is to be in two tranches, the first being for £275,000 in July and the second of £250,000 in August. Binding commitments for the full amount of £525,000 have been received by the Company and the first tranche of £275,000 has been subscribed in full.

Commenting on the fundraising Graham Lay, Chief Executive Officer of 3D said:

"As the company continues to progress its commercialisation activities, with the primary emphasis on the North American market the ongoing support of our shareholders is very much appreciated."

 

The directors accept responsibility for the content of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1624 679000
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
St Helens Capital Partners LLP Mark Anwyl	+44 (0) 207 368 6959
Buchanan Communications Diane Stewart, Carrie Clement	+44 (0) 207 466 5000

Notes to Editors:

CarieScan PRO™

The PRO™ is a highly accurate, easy to use, hand held device for the early detection and monitoring of dental caries (tooth decay). The PRO™ already has CE Mark and FDA 510K approval for sale in Europe and the USA.

The CarieScan PRO™ measures the presence of tooth decay earlier and more accurately than any other device on the market and is more than 90% accurate in detecting both sound and carious teeth, well ahead of other methods. It detects "hidden" decay, providing dental practitioners with the opportunity to arrest or even reverse decay, driving the trend towards preventative dental care.

The lightweight caries detection monitor not only offers best-in-class performance for decay detection but also allows easy monitoring of the effect of treatment regimes to show decay advancement or regression, thus enabling dentists to tailor treatment to the needs of the patient at a low cost.  The CarieScan PRO™ consists of a hand piece and a disposable sensor which is held against the tooth being examined in a process which takes approximately 4 seconds per tooth with the result displayed on the CarieScan PRO™.

3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
(PLUS ticker 3DDP)

CFO Appointment

Following last month's announcement regarding the completion of an exclusive agreement between CarieScan Ltd, 3D's main operating subsidiary, and Patterson Dental, the largest distributor of dental equipment in North America, for the distribution of the Company's CarieScan PRO™ ("PRO™") product in the USA, 3D is pleased to announce the strengthening of its Board with immediate effect through the appointment of Oliver Cooke to the post of Chief Finance Officer.

Mr Cooke (55) is a Chartered Accountant and has over 30 years of financial and business development experience gained in a range of quoted and private companies. Mr Cooke also currently holds the post of Executive Chairman of St Helens Capital Partners LLP, a corporate finance boutique and the largest PLUS Market Corporate Advisor by number of clients.

Mr Cooke's most recent public company role was as Executive Chairman of AIM-listed Multi Group Plc. When he joined the business in 2003 it was heavily loss making and had a market capitalisation of c. £2.5 million. At the time of his departure in 2007 the business has been fully restructured, had moved into a new market sector and its market capitalisation had grown to c. £18.4 million.

Graham Lay, Chief Executive Officer of 3D Diagnostic Imaging said, "We are very pleased that Oliver has accepted this role at this important time for the Company.  He brings with him solid financial experience and his knowledge of the Company's business and long-term strategies is unmatched.."

Oliver Cooke commented, "3D is a young company with terrific growth prospects and I am delighted to be joining a very capable team and look forward to helping them with the delivery of that growth". 

The directors accept responsibility for the content of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
St Helens Capital Partners LLP Mark Anwyl	+44 (0) 207 368 6959
Buchanan Communications Diane Stewart	+44 (0) 207 466 5000

Notes to Editors:

CarieScan PRO™

The PRO™ is a highly accurate, easy to use, hand held device for the early detection and monitoring of dental caries (tooth decay). The PRO™ already has CE Mark and FDA 510K approval for sale in Europe and the USA.

The CarieScan PRO™ measures the presence of tooth decay earlier and more accurately than any other device on the market and is more than 90% accurate in detecting both sound and carious teeth, well ahead of other methods. It detects "hidden" decay, providing dental practitioners with the opportunity to arrest or even reverse decay, driving the trend towards preventative dental care.

The lightweight caries detection monitor not only offers best-in-class performance for decay detection but also allows easy monitoring of the effect of treatment regimes to show decay advancement or regression, thus enabling dentists to tailor treatment to the needs of the patient at a low cost.  The CarieScan PRO™ consists of a hand piece and a disposable sensor which is held against the tooth being examined in a process which takes approximately 4 seconds per tooth with the result displayed on the CarieScan PRO™.

3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
(PLUS ticker 3DDP)

CarieScan signs exclusive distribution deal with leading US distributor Patterson Dental

CarieScan Limited ("CarieScan"), the wholly owned subsidiary of 3D, a leading producer of handheld devices for the early detection and monitoring of tooth decay, is today pleased to announce that it has signed an exclusive agreement with Patterson Dental, for the distribution of the company's CarieScan PRO product in the USA. The CarieScan PRO is a highly accurate, easy to use, hand held device for the early detection and monitoring of dental caries (tooth decay).

Patterson Dental is the largest distributor of dental equipment in North America with revenues in the 2009 financial year in excess of $2.1bn. The USA is considered to be one of the World's largest homogenous dental markets and is served by over 165,000 dental practices.

Patterson has placed its first order with CarieScan for stock as it prepares to sell to its US customer base. 

Commenting on the agreement with Patterson Dental, Graham Lay, Chief Executive Officer of 3D said:

"This agreement is of particular significance to CarieScan, and its parent company 3D, as it marks the transformation of the group from a product development business to a commercial enterprise with significant growth potential.  We believe that this agreement will be the first of many and the directors are in ongoing discussions with potential distributors in other major market places."

John Bettencourt, VP of Marketing, Equipment and Technical Service of Patterson Dental, said:

"We are delighted to have reached agreement with CarieScan to distribute this exciting new technology. We believe that the US market will show substantial interest in the adoption of the CarieScan PRO as its dental decay detection device of choice and look forward to a year of progress."

The CarieScan PRO measures the presence of tooth decay earlier and more accurately than any other device on the market and is more than 90% accurate in detecting both sound and carious teeth, well ahead of other methods. It detects "hidden" decay, providing dental practitioners with the opportunity to arrest or even reverse decay, driving the trend towards preventative dental care.

The lightweight caries detection monitor not only offers best-in-class performance for decay detection but also allows easy monitoring of the effect of treatment regimes to show decay advancement or regression, thus enabling dentists to tailor treatment to the needs of the patient at a low cost.  The CarieScan PRO consists of a hand piece and a disposable sensor which is held against the tooth being examined in a process which takes approximately 4 seconds per tooth with the result displayed on the CarieScan PRO. 

The directors accept responsibility for the content of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
St Helens Capital Partners LLP Oliver Cooke Mark Anwyl	+44 (0) 207 368 6959
Buchanan Communications Diane Stewart	+44 (0) 207 466 5000

3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
(PLUS ticker 3DDP)

Result of General Meeting

3D confirms that at a General Meeting held yesterday, it was resolved that the Directors of the Company (the "Directors") be and they are empowered pursuant to Article 5.2 of the Articles of Association to allot shares for cash or grant rights to subscribe for, or convert any security into, shares in the Company (and in particular, but without limitation, the Directors be and are hereby authorised to issue one or more debt instruments convertible into shares in the Company) ("Rights") as if Article 5.2 of the Articles of Association did not apply to any such allotment or grant of or exercise of Rights, provided that this power shall be limited to shares (including those which may become issuable in respect of the exercise of any Rights) with an aggregate nominal value of £30,000.00, is in substitution for any existing authority and shall expire on the conclusion of the next Annual General Meeting of the Company after the passing of this resolution, save that the Company may before such expiry make an offer or agreement (including by way of the grant of any Rights) which would or might require shares to be allotted after such expiry and the Directors may allot shares in pursuance of any such offer or agreement (including following the exercise of any Rights) notwithstanding that the power conferred by this resolution has expired.

The shareholding present by proxy at the meeting was 98.35%.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
Buchanan Communications Diane Stewart Carrie Clement	+44 (0) 207 466 5000

3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
(PLUS ticker 3DDP)

PLUS Award Win

3D, whose wholly owned subsidiary CarieScan Limited ("CarieScan") is a producer of handheld devices for the early detection and monitoring of tooth decay, was honoured at this years PLUS+ Awards 2010 receiving the PLUS New Issue of 2009 accolade at the ceremony held in Grand Connaught Rooms, Covent Garden, London.

Full Story

3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
(PLUS ticker 3DDP)

CarieScan strengthens management team ahead of expansion

CarieScan Limited ("CarieScan"), the wholly owned subsidiary of 3D, a leading producer of handheld devices for the early detection and monitoring of tooth decay, is pleased to announce the key appointment of Bill Lees as Director of Operations with effect from 3 June 2010.

Bill joins CarieScan with over 10 years operations experience and a proven track record in material and resource planning and production management. He will be responsible for the day to day operations of CarieScan's manufacturing, research and development, quality and regulatory processes, reporting to Chief Executive Officer, Graham Lay, as the company prepares to scale-up manufacturing of the CarieScan PRO™.

The PRO™ already has a CE Mark and FDA 510(k) clearance enabling market access in Europe and the USA and is currently being used by dental schools in two leading US universities in research and evaluation of "hidden" dental decay. CarieScan is working towards its first US distribution deal. The PRO™ provides dental practitioners with the opportunity to arrest or even reverse decay, driving the trend towards preventative dental care.

Commenting on the appointment, Graham Lay, Chief Executive Officer of 3D Diagnostic Imaging said:
"This is a key appointment for CarieScan and I am delighted that Bill, with his wealth of operational expertise in the management and delivery of complex projects, has agreed to join the team.

"He will be a major asset to CarieScan and invaluable as we scale-up manufacture of the PRO™, and enter into the next phase of our development, the commercial manufacture and sale of the PRO™."

Bill Lees commented:
 "CarieScan has enjoyed great success over the past 18 months having signed its first distribution deal in the UK, and is geared for even greater success over the coming years. I am delighted to be joining a company with such prospects and am coming into the business at a very exciting time as talks with distribution partners in both the US and Canada come closer to completion."

The Directors of 3D Diagnostic Imaging Plc accept responsibility for the contents of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
St Helens Capital Partners LLP Oliver Cooke Mark Anwyl	+44 (0) 207 937 4446
Buchanan Communications Diane Stewart Carrie Clement	+44 (0) 207 466 5000

Notes to Editors:

CarieScan PRO™

The CarieScan PRO™ measures the presence of tooth decay earlier and more accurately than any other device on the market and is more than 90% accurate in detecting both sound and carious teeth, well ahead of other methods. It detects "hidden" decay, providing dental practitioners with the opportunity to arrest or even reverse decay, driving the trend towards preventative dental care.

The lightweight caries detection monitor not only offers best-in-class performance for decay detection but also allows easy monitoring of the effect of treatment regimes to show decay advancement or regression, thus enabling dentists to tailor treatment to the needs of the patient at a low cost.  The CarieScan PRO™ consists of a hand piece and a disposable sensor which is held against the tooth being examined in a process which takes approximately 4 seconds per tooth with the result displayed on the CarieScan PRO™.

3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
(PLUS ticker 3DDP)

Notice of General Meeting

3D is pleased to announce that it has recently sent to shareholders a notice of General Meeting to be held on Thursday 27 May 2010 for the purpose of amending the Company's articles of association in order to give the Directors flexibility to issue new Ordinary Shares for cash as if the rights of pre-emption set out in Article 5.2 of the Company's Articles of Association did not apply to such an allotment. 

The Directors of 3D Diagnostic Imaging Plc accept responsibility for the contents of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
Buchanan Communications Diane Stewart Carrie Clement	+44 (0) 207 466 5000

3D DIAGNOSTIC IMAGING PLC
("3D" or "the Company")
(PLUS ticker 3DDP)

Shares in Issue

In accordance with the Disclosure and Transparency Rules, the Directors of 3D Diagnostic Imaging Plc (the "Company") confirm that the Company has 108,004,285 Ordinary Shares of 0.1p each in issue. The Company's total issued share capital is £108,004.

The Directors of 3D Diagnostic Imaging Plc accept responsibility for the contents of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
Buchanan Communications Diane Stewart Jennie Spivey Carrie Clement	+44 (0) 207 466 5000

CarieScan Ltd targets US market for its CarieScan PRO™

- one of the worlds most advanced dental decay detection devices

 

CarieScan Limited ("CarieScan"), the wholly owned subsidiary of PLUS-quoted holding company 3D, will cosponsor the International Caries Detection & Assessment System Foundation's International Workshop ('ICDAS') being held at Temple University, Philadelphia, USA next month (26-28 April) as discussions with distributors of the product continue in the US and Canada.

The company's lead product the CarieScan PRO™ ("PRO™") is an innovative handheld dental device that enables the early detection and monitoring of tooth decay including the reversible early stages.

CarieScan's Chief Executive Officer Graham Lay will be attending the ICDAS Workshop together with invited dental practitioners from around the world including the US, UK, Denmark, Germany, Columbia and Kuwait. Representatives from 10 universities will be debating new assessment, diagnosis and management protocols for caries that focus on caries prevention and control as they develop a new Caries Management System.

CarieScan recently appointed Professor Nigel Pitts, Professor of Dental Health at the University of Dundee and Co-Chair of the ICDAS Foundation as Chairman to CarieScan's newly formed Scientific Advisory Board ('Board').

The Board is responsible for improving understanding of evidence around electrical detection and monitoring of caries and how this can be applied to improve patient care.

Through Professor Pitts, three of the world's leading dental schools have also commenced research and evaluation using the CarieScan PRO™. The schools are Maurice H. Kornberg School of Dentistry Temple University, Philadelphia USA, New York University College of Dentistry, NY, USA and the University of Dundee Dental School, Scotland.

Graham Lay, CEO of CarieScan said, "The values of CarieScan and what we are looking to achieve with the CarieScan PRO™ are very much mirrored by the ICDAS Foundation in its objective to find a preventive and quantitative system to treat hidden caries. By conversing with universities we are getting the device recognised at a grass root level, enabling the PRO™ to be established with future dentists as the future of modern dentistry.

"The PRO™ is believed to be the most advanced decay detection device developed to date enabling the dental practitioner to truly assess the state of health of a person's teeth even during the reversible early stages of decay when a corresponding visual examination and X-ray may reveal nothing."

The Directors of 3D Diagnostic Imaging Plc accept responsibility for the contents of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
St Helens Capital Partners LLP Oliver Cooke Mark Anwyl	+44 (0) 207 368 6959
Buchanan Communications Diane Stewart Jennie Spivey Carrie Clement	+44 (0) 207 466 5000

Interim Results for the six months ended 31 December 2009

3D today announces its interim results for the six months ended 31 December 2009.

3D is the owner of intellectual property for the impedance technology platform which includes the ability to measure osteoporosis. Its wholly owned subsidiary, CarieScan Limited ("CarieScan" or together with 3D "the Group"), is the leading producer of handheld devices for the early detection and monitoring of tooth decay.

Highlights

• FDA 510(k) clearance obtained to market the CarieScan PROtm in the United States
• Exclusive UK distribution deal with Clark Dental
• Discussions with international distribution partners (principally North American) progressing
• £787,500 raised through a private placement of new shares principally with existing investors
• Three leading US and UK dental schools are commencing use of the CarieScan PROtm in research and student training
• Renowned dental expert, Professor Nigel Pitts appointed Chairman of the newly established Scientific Advisory Board
• Confident outlook for 2010

James Noble, Non-executive Chairman of 3D said: "During the next six months the primary emphasis of the business will be on the negotiation of distribution agreements within the North American marketplace. Successful assessment of the PRO has already taken place in Canada, with discussions there well advanced. We look forward to announcing further progress on this in due course. The Directors are confident of the Group's prospects for the coming year."

The Directors of 3D Diagnostic Imaging Plc accept responsibility for the contents of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
St Helens Capital Partners LLP Oliver Cooke Mark Anwyl	+44 (0) 207 368 6959
Buchanan Communications Diane Stewart Jennie Spivey Carrie Clement	+44 (0) 207 466 5000

Full Release

CarieScan Scientific Advisory Board Chairman Appointed
3 Leading Dental Schools to commence using the PRO™ for Research and Training

3D Diagnostic Imaging PLC, whose subsidiary, CarieScan Limited (“CarieScan”), is a leading producer of handheld devices for the early detection and monitoring of tooth decay, is pleased to announce that Professor Nigel Pitts, Professor of Dental Health at the University of Dundee, has been appointed Chairman to CarieScan’s newly formed Scientific Advisory Board (“Board”). 

The Board will be responsible for improving understanding of evidence around electrical caries detection and monitoring and how this can be applied to improve patient care. 

The Company today also announces that through Professor Pitts, three of the world’s leading dental schools will commence research and evaluation using the CarieScan PRO™. The schools are Maurice H. Kornberg School of Dentistry Temple University, Philadelphia USA, New York University College of Dentistry, NY, USA and the Dundee University Dental School, Scotland. 

This development is of key strategic importance to CarieScan, as the Company works towards its first US distribution deal following obtaining FDA 510K approval for the CarieScan PRO™ in December last year.

Professor Pitts has had an unusually broad career spanning, clinical practice, scientific and clinical research and public health. Following appointments in London and Hong Kong he joined the University of Dundee where he is currently Director of the Centre for Clinical Innovations, Director of the Dental Health Services & Research Unit and leads the Medical School’s Centre for Primary Care and Population Research.

Commenting on the appointment, Graham Lay, Chief Executive Officer of 3D Diagnostic Imaging said:

“We are delighted to have Nigel’s support for our CarieScan technology. He is acknowledged as a global opinion leader on dental caries. His outstanding experience in the field of dentistry, continued work in preventative care of hidden caries and involvement as co-chair of The International Caries Detection and Assessment System Foundation will be invaluable to CarieScan and accelerate its growth in worldwide markets.

The Directors of 3D Diagnostic Imaging Plc accept responsibility for the contents of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
St Helens Capital Partners LLP Oliver Cooke Mark Anwyl	+44 (0) 207 937 4446
Buchanan Communications Diane Stewart Jennie Spivey Carrie Clement	+44 (0) 207 466 5000

Notes to Editors:

CarieScan PRO™

The CarieScan PRO™ measures the presence of tooth decay earlier and more accurately than any other device on the market and is more than 90% accurate in detecting both sound and carious teeth, well ahead of other methods. It detects “hidden” decay, providing dental practitioners with the opportunity to arrest or even reverse decay, driving the trend towards preventative dental care.

The lightweight caries detection monitor not only offers best-in-class performance for decay detection but also allows easy monitoring of the effect of treatment regimes to show decay advancement or regression, thus enabling dentists to tailor treatment to the needs of the patient at a low cost.  The CarieScan PRO™ consists of a hand piece and a disposable sensor which is held against the tooth being examined in a process which takes approximately 4 seconds per tooth with the result displayed on the CarieScan PRO™.

 

3D Diagnostic Imaging PLC, a holding company whose wholly owned subsidiary, CarieScan Limited, is a leading producer of handheld devices for the early detection and monitoring of tooth decay, announces that at its Annual General Meeting on Friday 22 January 2010 the following resolutions were duly passed.

Ordinary Business
Resolution 1	THAT the Company's Annual Report and Accounts for the financial period ended 30 June 2009 together with the reports of the directors and auditors thereon be and are achieved.
Resolution 2	THAT James Cunningham-Davis, who retires by rotation and offers himself for re-election in accordance with the Articles of Association, be and is re-elected as a director of the Company.
Resolution 3	THAT Pritesh Ramesh Desai, who retires by rotation and offers himself for re-election in accordance with the Articles of Association, be and is re-elected as a director of the Company.
Resolution 4	THAT Graham Robert Lay, who has been appointed as a Director by the Board since 19 August 2008, retires and offers himself for re-election in accordance with the Articles of Association, be and is re-elected as a Director.
Resolution 5	THAT James Julian Noble, who has been appointed as a Director by the Board since 13 February 2009, retires and offers himself for re-election in accordance with the Articles of Association, be and is re-elected as a Director.
Resolution 6	THAT Deloitte, Chartered Accountants, be and are re-appointed as auditors of the Company for the ensuing year and that the Directors be authorised to determine their remuneration.
Special Business
Resolution 7	That the Directors be and they are empowered pursuant to Article 5.2 of the Articles of Association to allot shares for cash as if Article 5.2 of the Articles of Association did not apply to any such allotment, provided that this power shall be limited to shares with an aggregate nominal value of £11,000.00, is in substitution for any existing authority and shall expire on the conclusion of the next Annual General Meeting of the Company after the passing of this resolution, save that the Company may before such expiry make an offer or agreement which would or might require shares to be allotted after such expiry the Directors may allot shares in pursuance of any such offer or agreement notwithstanding that the power conferred by this resolution has expired.

The Directors of 3D Diagnostic Imaging Plc accept responsibility for the contents of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
St Helens Capital Partners LLP Oliver Cooke	+44 (0) 207 937 4446
Buchanan Communications Diane Stewart Jennie Spivey Carrie Clement	+44 (0) 207 466 5000

The Company is pleased to announce that it has today appointed Fisher Corporate Plc to act as its PLUS corporate adviser.

St Helens Capital Partners LLP will continue to act as the Company's financial adviser.

The Directors of 3D Diagnostic Imaging Plc accept responsibility for the contents of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
Fisher Corporate Plc Gary Miller	+44 (0) 207 388 7000
St Helens Capital Partners LLP Oliver Cooke	+44 (0) 207 937 4446
Buchanan Communications Diane Stewart Jennie Spivey Carrie Clement	+44 (0) 207 466 5000

3D, whose subsidiary CarieScan is a producer of handheld devices for the early detection and monitoring of tooth decay, announces that on 21 December 2009 it raised a total of £37,500 by way of a placing of 500,000 new ordinary shares of 0.1p each. 250,000 ordinary shares were placed with the market maker Winterflood Securities at a price of 7 pence per share in order to satisfy market demand for the Company's shares. A further 250,000 ordinary shares were purchased in equal proportions by James Cunningham-Davis and Pritesh Desai, both Non-Executive Directors of the Company, at a price of 8 pence per share.

The proceeds from this placing will be used for working capital within the Company. 

Following this transaction, James Cunningham-Davis and Pritesh Desai are each interested in a total of 125,000 ordinary shares in the Company representing 0.12% of the issued share capital of the Company. The total Directors' shareholdings are now 12,091,500 ordinary shares representing 11.22% of the issued share capital of the Company. Following this issue, there are a total of 107,804,285 ordinary shares in issue.

The Directors of 3D Diagnostic Imaging PLC are responsible for the contents of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
St Helen's Capital Partners LLP Oliver Cooke Mark Anwyl	+44 (0) 207 368 6959
Buchanan Communications Diane Stewart Jennie Spivey Carrie Clement	+44 (0) 207 466 5000

3D, whose subsidiary, CarieScan Limited ("CarieScan"), is a leading producer of handheld devices for the early detection and monitoring of tooth decay, is pleased to announce that it has received 510(k) clearance from the Food & Drug Administration ("FDA"), allowing the CarieScan PROtm to be marketed in the United States of America ("US"). 

This is a key milestone for CarieScan which opens up the major diagnostic market in the US to CarieScan PROtm,, providing a basis for securing a US distribution partner, giving the Company the opportunity to significantly increase product sales. 

The CarieScan PROtm measures the presence of tooth decay earlier and more accurately than any other device on the market and is more than 90% accurate in detecting both sound and carious teeth, well ahead of other methods. It detects "hidden" decay, providing dental practitioners with the opportunity to arrest or even reverse decay, driving the trend towards preventative dental care.

The lightweight caries detection monitor not only offers best-in-class performance for decay detection but also allows easy monitoring of the effect of treatment regimes to show decay advancement or regression, thus enabling dentists to tailor treatment to the needs of the patient at a low cost. The CarieScan PROtm consists of a hand piece and a disposable sensor which is held against the tooth being examined in a process which takes approximately 4 seconds per tooth with the result displayed on the CarieScan PROtm .  

James Noble, Non-executive Chairman of 3D Diagnostic Imaging said:

"The approval is the culmination of a very successful year for 3D in that we have successfully achieved a PLUS market listing, completed two significant fundraisings, and secured a UK distribution agreement. We now intend to begin discussions with potential distribution partners with the objective of securing agreements for the sale of CarieScan PROtm in the US during the coming months." 

The directors accept responsibility for the content of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
St Helen's Capital Partners LLP Oliver Cooke Mark Anwyl	+44 (0) 207 368 6959
Buchanan Communications Diane Stewart Jennie Spivey Carrie Clement	+44 (0) 207 466 5000

Full Story

 

Full Story

 

3D Diagnostic Imaging plc (PLUS:3DDP), has been notified that the name of its PLUS Corporate Adviser has been changed to St Helen's Capital Partners LLP.

The Directors of 3D Diagnostic Imaging plc are responsible for the content of this announcement.

Enquiries:

3D Diagnostic Imaging Plc Graham Lay, CEO	+44 (0) 1382 560910
St Helen's Capital Partners LLP Oliver Cooke	+44 (0) 207 368 6959
Buchanan Communications Diane Stewart Jennie Spivey Carrie Clement	+44 (0) 207 466 5000

Full story

 

Admission Document

 

3D Diagnostic Imaging Plc are pleased to announce the launch of an Investor Relations website.